Kailera Therapeutics Inc. (KLRA)
NASDAQ: KLRAHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
KLRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.37B
- EPS (TTM)
- -$4.37
- Dividend yield
- None
- 52-week range
- 9.85 – 28.23
- Day range
- 10.50 – 11.12
- Volume / Avg
- 1.09M / 844.17K
- Beta
- —
- Shares outstanding
- 129.64M
- Next earnings
- Nov 4, 2026
52-week range
KLRA stock today
Kailera Therapeutics (KLRA) closed at $10.53 on Oct 7, down 2.77% (-$0.30), versus the S&P 500's 0.22% decline. At this level, KLRA sits near the bottom of its 52-week range of $9.85 to $28.23: 62.7% below the high, set on Apr 20, 2026 and 6.9% above the low. Kailera Therapeutics has posted a net loss over the last twelve months (EPS of -$4.37), so its P/E ratio is not meaningful.
Kailera Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Kailera Therapeutics
Company profileKailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ronald C. Renaud Jr., M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 145
- IPO year
- 2026
- Website
- kailera.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$42.40+302.66%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
Kailera Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANABAnaptysBio Inc. | 45.65 | -4.68% | $1.36B | vs KLRA |
| OMEROmeros Corporation | 18.75 | +1.30% | $1.36B | vs KLRA |
| INBXInhibrx Biosciences Inc. | 93.36 | -0.05% | $1.37B | vs KLRA |
| NKTRNektar Therapeutics | 40.26 | +0.88% | $1.37B | vs KLRA |
| COAGHemab Therapeutics Holdings Inc. | 28.70 | +1.16% | $1.34B | vs KLRA |
| AAPGAscentage Pharma Group International American Depository Shares | 14.94 | -7.15% | $1.40B | vs KLRA |
| TYRATyra Biosciences Inc. | 20.39 | +0.74% | $1.40B | vs KLRA |
| DRTSAlpha Tau Medical Ltd. | 14.25 | -1.59% | $1.32B | vs KLRA |
Indexes, lists and sector
Appears in lists
Kailera Therapeutics stock FAQ
What is Kailera Therapeutics's stock price today?
KLRA last traded at $10.53 as of Oct 7, 4:00 PM EDT, down 2.77% on the day. Prices are delayed at least 15 minutes.
When is Kailera Therapeutics's next earnings date?
Kailera Therapeutics is expected to report earnings on Wednesday, November 4, 2026.
Who is Kailera Therapeutics's CEO?
Mr. Ronald C. Renaud Jr., M.B.A. is the chief executive officer of Kailera Therapeutics Inc., which has about 145 employees.
What is the KLRA 52-week high?
The 52-week high for KLRA is $28.23 and the 52-week low is $9.85. The stock is currently 62.7% below its high.